• Suofeng Sun, Yuan Li, Bowei Liu, Bingyong Zhang, Shuangyin Han, and Xiuling Li.
• Department of Gastroenterology, Henan Provincial People's Hospital, Zhengzhou, China.
• Arch Med Sci. 2020 Jan 1; 16 (2): 407-413.

IntroductionDue to the increasing resistance to nucleot(s)ide analogs in patients with chronic hepatitis B, development of new antiviral drugs to eradicate hepatitis B virus is still urgently needed.Material And MethodsTo date, most studies on evaluating anti-HBV drugs have been performed using cell lines where the HBV genomic DNA is chromosomally integrated, e.g. Hep2.2.15 in HBV-infected livers of the viral episomal genome replicates in the nucleus and covalently closed circular DNA (cccDNA) serves as a transcriptional template. Another option involves the use of HBV-infected cells of HepaRG or NTCP-overexpressing cells. However, the development of the infection system is expensive and laborious, and its HBV expression level remained low.ResultsCompared to HuH7 cells, the established stable cell lines based on episomal-type pEB-Multi vectors can been expressed HBV wild-type by qRT-PCR and immunoblotting (p < 0.05). These two vectors are also sensitive to Entecavir and against nucleoside analog Lamivudine in mutants cellines.ConclusionsIt is worth demonstrating how useful the established cell system is for evaluating antiviral agents and their mechanisms of action.Copyright: © 2018 Termedia & Banach.

1 keywords...

hide…